drugset / Trial / NCT02946359
A+C in Metastatic Lung Adenocarcinoma Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification
Timeline
- Start
- 2016-07
- Primary completion
- 2017-10
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Crizotinib | Small molecule | 250 mg | Oral |